Shanwan Bio key facts
- Manufacturer of complex sustained-release dosage forms intended for controlled drug delivery purposes.
- Notable investors include Suzhou Wujiang Venture Capital, Shenzhen Rurisheng Equity Investment, Jiangsu Jinqiao Private Equity Fund Management, Kangli Elevator, Sihai New Material Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Shanwan Bio: the Monday email on marks, rounds and moves
Shanwan Bio funding rounds
No funding rounds for Shanwan Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Shanwan Bio investors
7 investors are on record for Shanwan Bio, including Suzhou Wujiang Venture Capital, Shenzhen Rurisheng Equity Investment, Jiangsu Jinqiao Private Equity Fund Management and Kangli Elevator.
About Shanwan Bio
Manufacturer of complex sustained-release dosage forms intended for controlled drug delivery purposes. The company offers in-situ gel matrix technology, peptide and small molecule formulation capabilities, GMP-compliant pilot and commercial production lines including prefilled syringes and lyophilized injectables, CDMO services for formulation development, analytical testing, stability studies, regulatory support, and technology transfer processes, enabling pharmaceutical developers and biopharma partners to accelerate long-acting product development, enhance therapeutic efficacy, ensure quality compliance, and reduce time-to-market.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2018
- Employees
- 1
- Website
- shanwanbiotech.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Shanwan Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.